The LivaNova VNS study reported sustained seizure reductions among children and adults with drug-resistant epilepsy. The company announced the full 36-month publication on October 23, while the underlying journal article was published online October 5.
The prospective, multinational observational study evaluated modern vagus nerve stimulation devices across 61 sites in 16 countries. Investigators followed participants receiving VNS Therapy as an adjunct to their existing epilepsy care.
LivaNova VNS Study Reports Durable Seizure Reductions
The published analysis included 531 first-time implant recipients, with 426 completing the 36-month follow-up. That represents an 80% retention rate and provides a large real-world cohort for long-term assessment.
| 36-month measure | Reported outcome |
|---|---|
| Median seizure-frequency reduction | 76% |
| At least 50% seizure reduction | 64% |
| Complete seizure freedom | 16% (64 of 392) |
| Improved quality of life | 45% (174 of 391) |
| Study retention | 80% |
The figures come from LivaNova’s October 23 announcement and its cited peer-reviewed study. Nearly half of participants with available data experienced an 80% or greater seizure reduction.
Hospital and Emergency Visits Also Declined
Seizure-related hospitalizations fell from 27% of participants at baseline to 7% after 36 months. Emergency department visits declined from 32% to 15%, while 45% of participants reported improved quality of life.
The results add a clinical-data angle to Fusion’s coverage of Microsoft’s medical diagnosis research and Tempus AI’s healthcare data agreements. Those developments also show how medical technology companies are trying to demonstrate measurable patient or research value.
Observational Design Limits Causal Conclusions
CORE-VNS was open-label and observational rather than a randomized controlled trial. Participants and clinicians knew the treatment being used, while follow-up outcomes were available for fewer people than the broader study enrollment.
Those limitations mean the findings should not be interpreted as proof that VNS Therapy caused every reported improvement. Adverse events were consistent with product labeling and included voice changes, breathing difficulty and cough among the more commonly reported categories.
Fusion recently covered Bolt’s clinical-program financing, underscoring how trial design and financing both shape healthcare-company risk. This article is informational and does not provide medical advice. Patients should discuss epilepsy treatment options, eligibility and device risks with qualified specialists.
Elsy kanana
Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.
